Takeda Oncology
Sharon Friedlander is an accomplished professional in the field of oncology and translational medicine with extensive experience in leading research and development initiatives. Currently serving as the Associate Director and Reverse Translation Development Lead at Takeda Oncology since September 2017, Sharon has also held the position of Associate Director, Translational Medicine Lead for the IO-ODDU division. Prior to Takeda, Sharon worked at Deciphera Pharmaceuticals as Associate Director, Head of Translational Medicine, and at Karyopharm Therapeutics Inc. as Associate Director, Head of Translational Research, and Senior Scientist. Earlier career experience includes a role at Metamark Genetics as Senior Scientist and Corporate-Pharma Partnerships Lead. Sharon's educational background includes a Postdoctoral Fellowship in Integrative Cancer Research from the Massachusetts Institute of Technology and a Ph.D. in Medical Sciences from The Hebrew University Hadassah Medical School, along with a Master's in Microbiology and a Bachelor's in Life Science from The Hebrew University.
This person is not in any teams
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.